John H. Maduro

Dr. John H. Maduro

radiation oncology, UMC Groningen, Groningen, The Netherlands
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2017 in Journal of Clinical Oncology
Verified
Journal Article
Open access
VBVeerle A.B. van Den Bogaard
Veerle A.B. van Den Bogaard
BTBastiaan D.P. Ta
Bastiaan D.P. Ta
Arjen Van der SchaafArjen Van der Schaaf
Arjen Van der Schaaf
ABAngelique B. Bouma
Angelique B. Bouma
AMAstrid M.H. Middag
Astrid M.H. Middag
ACAnne P.G Crijns
Anne P.G Crijns
Purpose: A relationship between mean heart dose (MHD) and acute coronary event (ACE) rate was reported in a study of patients with breast cancer (BC). The main objective of our cohort study was to validate this relationship and investigate if other dose-distribution parameters are better predictors for ACEs than MHD. Patients and Methods: The cohort consisted of 910 consecutive female patients with BC treated with radiotherapy (RT) after breast-conserving surgery. The primary end point was cumulative incidence of ACEs within 9 years of follow-up. Both MHD and various dose-distribution parameters of the cardiac substructures were collected from three-dimensional computed tomography planning data. Results: The median MHD was 2.37 Gy (range, 0.51 to 15.25 Gy). The median follow-up time was 7.6 years (range, 0.1 to 10.1 years), during which 30 patients experienced an ACE. The cumulative incidence of ACE increased by 16.5% per Gy (95% CI, 0.6 to 35.0; P = .042). Analysis showed that the volume of the left ventricle receiving 5 Gy (LV-V5) was the most important prognostic dose-volume parameter. The most optimal multivariable normal tissue complication probability model for ACEs consisted of LV-V5, age, and weighted ACE risk score per patient (c-statistic, 0.83; 95% CI, 0.75 to 0.91). Conclusion: A significant dose-effect relationship was found for ACEs within 9 years after RT. Using MHD, the relative increase per Gy was similar to that reported in the previous study. In addition, LV-V5 seemed to be a better predictor for ACEs than MHD. This study confirms the importance of reducing exposure of the heart to radiation to avoid excess risk of ACEs after radiotherapy for BC.

1 October 2021 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
RMRobert W. Mutter
Robert W. Mutter
JCJ. Isabelle Choi
J. Isabelle Choi
RJRachel B. Jimenez
Rachel B. Jimenez
YKYoulia M. Kirova
Youlia M. Kirova
MFMarcio Fagundes
Marcio Fagundes
SMShannon M. MacDonald
Shannon M. MacDonald

1 October 2014 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
MMMirjam E. Mast
Mirjam E. Mast
EVEline J. Vredeveld
Eline J. Vredeveld
HCHerman M. Credoe
Herman M. Credoe
JEJaap van Egmond
Jaap van Egmond
MHMark W. Heijenbrok
Mark W. Heijenbrok
JMJohn H. Maduro
John H. Maduro
Purpose In left-sided breast cancer radiotherapy, tangential intensity modulated radiotherapy combined with breath-hold enables a dose reduction to the heart and left anterior descending (LAD) coronary artery. Aim of this study was to investigate the added value of intensity modulated proton therapy (IMPT) with regard to decreasing the radiation dose to these structures. Methods In this comparative planning study, four treatment plans were generated in 20 patients: an IMPT plan and a tangential IMRT plan, both with breath-hold and free-breathing. At least 97 % of the target volume had to be covered by at least 95 % of the prescribed dose in all cases. Specifically with respect to the heart, the LAD, and the target volumes, we analyzed the maximum doses, the mean doses, and the volumes receiving 5–30 Gy. Results As compared to IMRT, IMPT resulted in significant dose reductions to the heart and LAD-region even without breath-hold. In the majority of the IMPT cases, a reduction to almost zero to the heart and LAD-region was obtained. IMPT treatment plans yielded the lowest dose to the lungs. Conclusions With IMPT the dose to the heart and LAD-region could be significantly decreased compared to tangential IMRT with breath-hold. The clinical relevance should be assessed individually based on the baseline risk of cardiac complications in combination with the dose to organs at risk. However, as IMPT for breast cancer is currently not widely available, IMPT should be reserved for patients remaining at high risk for major coronary events.

1 January 2018 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CRCatharina T.G. Roos
Catharina T.G. Roos
VBVeerle A.B. van Den Bogaard
Veerle A.B. van Den Bogaard
MGMarcel Greuter
Marcel Greuter
RVRozemarijn Vliegenthart
Rozemarijn Vliegenthart
ESEwoud Schuit
Ewoud Schuit
JMJohn H. Maduro
John H. Maduro

30 November 2020 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
Daniël Jonathan van der MeerDaniël Jonathan van der Meer
Daniël Jonathan van der Meer
IKIris Kramer
Iris Kramer
MMMarissa C. van Maaren
Marissa C. van Maaren
PDPaul J van Diest
Paul J van Diest
SLSabine C. Linn
Sabine C. Linn
AVAdri C. Voogd
Adri C. Voogd
Our study aimed to provide a comprehensive overview of trends in incidence, survival, mortality and treatment of first primary invasive breast cancer (BC), according to age, stage and receptor subtype in the Netherlands between 1989 and 2017. Data from all women diagnosed with first primary stage I to IV BC (N = 320 249) were obtained from the Netherlands Cancer Registry. BC mortality and general population data were retrieved from Statistics Netherlands. Age‐standardised incidence and mortality rates were calculated with annual percentage change (APC) and average annual percentage change (AAPC) statistics. The relative survival (RS) was used as estimator for disease‐specific survival. The BC incidence for all BC patients combined significantly increased until 2013 from 126 to 158 per 100 000 person‐years, after which a declining trend was observed. Surgery became less extensive, but (neo‐)adjuvant systemic treatments and their combinations were given more frequently. The RS improved for all age groups and for most stages and receptor subtypes, but remained stable for all subtypes since 2012 to 2013 and since 2000 to 2009 for Stage IV BC at 15 years of follow‐up. Overall, the 5‐ and 10‐year RS increased from 76.8% (95% confidence interval [CI]: 76.1, 77.4) and 55.9% (95% CI: 54.7, 57.1) in 1989 to 1999 to 91.0% (95% CI: 90.5, 91.5) and 82.9% (95% CI: 82.2, 83.5), respectively, in 2010 to 2016. BC mortality improved regardless of age and overall decreased from 57 to 35 per 100 000 person‐years between 1989 and 2017. In conclusion, the BC incidence in the Netherlands has steadily increased since 1989, but the latest trends show promising declines. Survival improved markedly for most patients and the mortality decreased regardless of age.

25 November 2016 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
ABAnnelotte C.M. van Bommel
Annelotte C.M. van Bommel
PSPauline E.R. Spronk
Pauline E.R. Spronk
MPMarie‐Jeanne T.F.D. Vrancken Peeters
Marie‐Jeanne T.F.D. Vrancken Peeters
AJAgnes Jager
Agnes Jager
MLMarc Lobbes
Marc Lobbes
OAOn Behalf Of The Nabon Breast Cancer Audit
On Behalf Of The Nabon Breast Cancer Audit